title: [Subcutaneous continuous injection of octreotide decreased the tumor marker levels and induced cystic necrosis of the tumors in a case of pancreatic neuroendocrine tumor with multiple hepatic metastases].
abstract: For symptom alleviation, subcutaneous continuous injection of octreotide was administered to a patient with pancreatic neuroendocrine tumor (NET) accompanied by multiple hepatic metastases and ascites. The level of the tumor marker neuron-specific enolase decreased to the normal range and cystic necrosis of the tumors was confirmed. There have been some reports on the antineoplastic effects of octreotide on pancreatic NET; therefore, octreotide appears to be a valid option as a therapeutic agent in patients with highly advanced pancreatic NET, in whom administration of molecular targeted or anticancer agents is difficult because of a poor general status.
authors.affiliation: Department of Gastroenterology, Toyota Kosei Hospital.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Miura
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shibahara
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Morita
authors.forename: Kenichi
authors.initials: K
authors.lastname: Matsui
authors.forename: Yuya
authors.initials: Y
authors.lastname: Itoh
authors.forename: Junichi
authors.initials: J
authors.lastname: Shimizu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeuchi
authors.forename: Michihiko
authors.initials: M
authors.lastname: Narita
authors.forename: Daisaku
authors.initials: D
authors.lastname: Nishimura
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Katada
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D007279:Injections, Subcutaneous; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000097:blood / Q000188:drug therapy* / Q000556:secondary; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D015282:Octreotide